AXIOS August 5, 2024
Prescriptions for blockbuster drugs that treat diabetes, obesity and heart disease are soaring, but the mix of payers shows access to the drugs is far from equitable, per a study published in JAMA Health Forum.
Why it matters: Patients on Medicare and Medicaid appear less likely to be able to access the drugs than those with private coverage.
What they found: The UCLA-led study found a 442% increase in scripts for semaglutide — the active ingredient in diabetes drug Ozempic and anti-obesity and heart disease drug Wegovy — between January 2021 and December 2023.
- There were 2.6 million prescription fills in December 2023 but less than...
Today's Sponsors
Today's Sponsor